retatrutide clinical data Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide Results: 28.3% Weight Loss
Description
Learn more about this innovative treatment today and meet our team of leading healthcare professionals who care about your overall health
Our state-of-the-art facilities and affordable pricing ensure that high-quality care is within reach for our community
Weeks 17 onward: 12mg weekly maintenance for those in the highest arm
[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Yaribeygi H., Farrokhi F.R., Abdalla M.A., et al
During the titration period, doses of glimepiride were increased to 4 mg/day
This level of weight loss is significant because even a 5% to 10% reduction in body weight can improve metabolic health, lower blood pressure, and decrease the risk of conditions like fatty liver disease and obstructive sleep apnea
